الفهرس 
GENERAL INTRODUCTIONيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 125 |  |  |
| | | from | 125 | | |
المستخلص
Background: The Absorption Rates Of Mycophenolate Mofetil (MMF) And Enteric-Coated Mycophenolate Sodium (EC-MPS) May Be Influenced By The Concomitant Use Of Omeprazole.
Aim: We Aimed from This Study To Assess The Attainment Of Mycophenolic Acid (MPA) Area Under The Curve (AUC (0–12)) Target Levels For Both Formulations.
Methods: One Hundred Kidney Transplant Patients Were Recruited During Their Outpatient Visits, Including 50 On MMF And 50 On EC-MPS. At The Clinic, A Pre-Dose M MPA Sample (C0) Was Collected; Subsequently, The Participants Received The Proton-Pump Inhibitor Omeprazole Along With Either MMF Or EC-MPS. Two More Blood Samples Were Collected At 1.5 And 3.5 Hours And Used To Estimate AUC from Zero To 12 Hours.
Results: The Mean Number Of Months After Transplant Was 92 Months. The Median AUC (0–12) And C0 Results Were 62.2 Mg.H/L And 2.0 Mg/L For The MMF group And 71.9 Mg.H/L And 1.8 Mg/L For The EC-MPS group (P = 0.16 And 0.255, Respectively). Interestingly, 54% Of The MMF group And 62% Of The EC-MPS group Showed Aucs Above The Target Values. The Correlation Between MPA C0 And The Predicted AUC Was Poor In Both Groups.
Conclusion: Omeprazole Can Be Safely Co-Administered With Either MMF Or EC-MPS, As It Did Not Compromise The MPA Exposure. Unexpectedly, A High Percentage Of Patients Presented MPA Aucs Exceeding The Target Value, Indicating The Importance Of Periodical Assessment Of MPA Level.
Keywords: Kidney Transplant Patients, MMF, EC-MPS, MPA, AUC, Omeprazole.